evaluation of biomarkers of nafld in a cohort of morbidly obese patients评价非酒精性脂肪肝的生物标志物群病态肥胖患者.pdfVIP

Hindawi Publishing Corporation Journal of Nutrition and Metabolism Volume 2011, Article ID 369168, 7 pages doi:10.1155/2011/369168 Research Article Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients ¨ 1 1 ¨ 2 1 Julia Kalsch, Lars P. Bechmann, Hagen Kalsch, Martin Schlattjan, Jochen Erhard,3 Guido Gerken,1 and Ali Canbay1 1 Division of Gastroenterology and Hepatology, University Hospital Essen, 45122 Essen, Germany 2 Division of Cardiology, University Hospital Essen, 45122 Essen, Germany 3 Department of Surgery, Evangelisches Krankenhaus Dinslaken, 46535 Dinslaken, Germany Correspondence should be addressed to Ali Canbay, ali.canbay@uni-due.de Received 31 January 2011; Accepted 1 May 2011 Academic Editor: Duo Li ¨ Copyright © 2011 Julia Kalsch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hepatocyte apoptosis is a key event in nonalcoholic fatty liver disease (NAFLD), and serum apoptotic markers are emerging as surrogate markers for NAFLD. We studied the role of caspase-cleaved cytokeratin18 in the diagnosis of fibrosis in a cohort of 127 morbidly obese patients and also performed a review of the literature biomarkers of NAFLD and fibrosis. Here, we found that cleaved caspase 18 correlated with liver steatosis and liver injury as assessed by serum transaminase levels. Furthermore, hepatocyte apoptosis as assessed by cleaved CK18 and TUNEL staining correlated with the extent of fibrosis as assessed by Sirius Red staining